BeiGene (BGNE) Stock Price, News & Analysis

Company Overview

BeiGene, Ltd., through its subsidiaries, engages in the development and commercialization of oncology medicines worldwide. Its products include BRUKINSA to treat various blood cancers; TEVIMBRA to treat various solid tumor and blood cancers; PARTRUVIX for the treatment of various solid tumor malignancies; XGEVA to treat bone metastases from solid tumors and multiple myeloma, as well as giant cell tumor of bone; BLINCYTO to treat acute lymphoblastic leukemia; KYPROLIS to treat R/R multiple myeloma; REVLIMID to treat multiple myeloma; VIDAZA to treat myelodysplastic syndromes, chronic myelomonocyte leukemia, and acute myeloid leukemia; SYLVANT to treat idiopathic multicentric castleman disease; QARZIBA to treat neuroblastoma; POBEVCY to treat metastatic colorectal cancer, liver cancer, and non-small cell lung cancer (NSCLC); BAITUOWEI, to treat breast and prostate cancers; TAFINLAR and MEKINIST to treat NSCLC and melanoma; VOTRIENT for advance renal cell carcinoma; AFINITOR for advance renal cell carcinoma, NET, SEGA, & breast cancers; and ZYKADIA to treat ALK + NSCLC. The company is also developing inhibitors comprising Sonrotoclax (BGB-11417), BGB-10188, BGB-21447, Ociperlimab (BGB-A1217), Surzebiclimab (BGB-A425), BGB-15025, BGB-26808, Lifirafenib (BGB-283), BGB-3245, BGB-30813, and BGB-43395; antibodies, including Zanidatamab, BGB-A445, and BGB-A3055, as well as BGB-16673, a BTK-targeted CDAC, and BGB-24714, a SMAC mimetic. It has collaborations with Shoreline Biosciences, Inc., Amgen Inc., Novartis AG, Bristol Myers Squibb company, Shandong Luye Pharmaceutical Co., Ltd., Nanjing Leads Biolabs, Inc., EUSA Pharma, Assembly Biosciences, Inc., Bio-Thera Solutions, Ltd., and Nanjing Leads Biolabs Co., Ltd. The company was incorporated in 2010 and is based in Grand Cayman, the Cayman Islands.

Key Stats

• Today's Range: N/A
• 50-Day Range: $174.72 to $217.22
• 52-Week Range: N/A
• Volume: 331,608 shs
• Average Volume: 342,033 shs
• Market Capitalization: $18.03 billion
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $274.20
• Consensus Rating: Buy

BeiGene Stock Analysis - MarketRank™

BeiGene scored higher than 34% of companies evaluated by MarketBeat, and ranked 748th out of 919 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.5 / 5
• Analyst Rating: Buy

Consensus Rating

BeiGene has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 5 buy ratings, no hold ratings, and no sell ratings.

Amount of Analyst Coverage

BeiGene has received no research coverage in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for BeiGene are expected to grow in the coming year, from ($5.64) to ($0.25) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of BeiGene is -22.42, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of BeiGene is -22.42, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Short Interest

• Score: N/A
• Short Interest Level: N/A

Short Interest

There is no current short interest data available for BGNE.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

BeiGene does not currently pay a dividend.

Dividend Growth

BeiGene does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Short Interest

There is no current short interest data available for BGNE.

News and Social Media

• Score: 1.1 / 5
• News Sentiment: N/A

Search Interest

2 people have searched for BGNE on MarketBeat in the last 30 days.

MarketBeat Follows

1 people have added BeiGene to their MarketBeat watchlist in the last 30 days.

Company Ownership

• Score: 0.8 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, BeiGene insiders have not sold or bought any company stock.

Percentage Held by Insiders

Only 7.43% of the stock of BeiGene is held by insiders.

Percentage Held by Institutions

48.55% of the stock of BeiGene is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

BGNE Stock Analysis - Frequently Asked Questions

How were BeiGene's earnings last quarter?

BeiGene, Ltd. (NASDAQ:BGNE) posted its quarterly earnings results on Tuesday, November, 12th. The company reported ($1.15) EPS for the quarter, missing the consensus estimate of ($1.11) by $0.04. The firm's revenue was up 28.2% on a year-over-year basis.

When did BeiGene IPO?

BeiGene (BGNE) raised $126 million in an initial public offering on Wednesday, February 3rd 2016. The company issued 5,500,000 shares at a price of $22.00-$24.00 per share. Goldman Sachs, Morgan Stanley and Cowen and Company acted as the underwriters for the IPO and Baird was co-manager.

Who are BeiGene's major shareholders?

BeiGene's top institutional investors include Twin Tree Management LP. Insiders that own company stock include Advisors Ltd Hhlr, Lai Wang, Bros Advisors Lp Baker, Xiaodong Wang, Xiaobin Wu, Titus B Ball, Julia Aijun Wang, John Oyler, Corazon (Corsee) D Sanders and Chan Henry Lee.
View institutional ownership trends.

What other stocks do shareholders of BeiGene own?

Based on aggregate information from My MarketBeat watchlists, some other companies that BeiGene investors own include NVIDIA (NVDA), Meta Platforms (META), Broadcom (AVGO), Adobe (ADBE), Advanced Micro Devices (AMD), ServiceNow (NOW) and Saia (SAIA).

Company Calendar

• Last Earnings: 11/12/2024
• Today: 8/01/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Pharmaceutical preparations
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:BGNE
• CIK: 1651308
• Web: www.beigene.com
• Phone: (345) 949-4123
• Fax: N/A
• Employees: 9,000
• Year Founded: 2010

Price Target and Rating

• Average Price Target for BeiGene: $274.20
• High Price Target: $300.00
• Low Price Target: $235.00
• Consensus Rating: Buy
• Rating Score (0-4): 3.00
• Research Coverage: 5 Analysts

Profitability

• EPS (Trailing Twelve Months): ($8.24)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$881.71 million
• Net Margins: -25.94%
• Pretax Margin: -24.07%
• Return on Equity: -25.12%
• Return on Assets: -14.95%

Debt

• Debt-to-Equity Ratio: 0.05
• Current Ratio: 1.93
• Quick Ratio: 1.72

Sales & Book Value

• Annual Sales: $3.32 billion
• Price / Sales: 0.00
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $37.10 per share
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: 97,618,000
• Free Float: 90,195,000
• Market Cap: $18.03 billion
• Optionable: Optionable
• Beta: 0.57